Get the Stockscreener App
3.24
2.70%
-0.09
Cytomx Therapeutics Inc stock is traded at $3.24, with a volume of 1.52M.
It is down -2.70% in the last 24 hours and down -2.41% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$3.33
Open:
$3.34
24h Volume:
1.52M
Relative Volume:
0.37
Market Cap:
$705.36M
Revenue:
$35.54M
Net Income/Loss:
$-59.14M
P/E Ratio:
-8.9084
EPS:
-0.3637
Net Cash Flow:
$-80.19M
1W Performance:
-10.50%
1M Performance:
-2.41%
6M Performance:
-41.52%
1Y Performance:
+35.56%
1-Day Range:
$3.20
$3.38
1-Week Range:
$3.20
$3.735
52-Week Range:
$1.72
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.24 | 705.36M | 35.54M | -59.14M | -80.19M | -0.3637 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CTMX stock holds focus after CytomX strategy update - AD HOC NEWS
CytomX Therapeutics, Inc.Common Stock (NQ: CTMX - FinancialContent
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
CytomX Therapeutics (CTMX) Holds Near Support After Slight DipUpthrust Pattern - dars.gov.et
CytomX Therapeutics updates investors on its pipeline progress amid Nasdaq listing - Ad-hoc-news.de
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why - Yahoo Finance
CytomX Therapeutics Q1 2026 Earnings: Narrower Net Loss Beats Expectations but Stock DeclinesEstimate Revision Count - dars.gov.et
CytomX Therapeutics focuses on its antibody-drug conjugate platform - Ad-hoc-news.de
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
CytomX Therapeutics outlines its oncology focus as investors watch Nasdaq trading - ad-hoc-news.de
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Value Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Microcap Value Benchmark Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell Microcap Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to book forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Price to earnings forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to EBIT forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Price to sales forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to revenue forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
CytomX Therapeutics, Inc. Actuals & Estimates (NASDAQ:CTMX) - TradingView
CTMX Forecast — Price Target — Prediction for 2027 - TradingView
CytomX Shareholders Approve Expanded Equity and Capital Plans - The Globe and Mail
Form 4 CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com India
CytomX Therapeutics Amends Equity Incentive and Employee Stock Purchase Plans Following 2026 Shareholder Approval – Minichart - Minichart
CytomX Therapeutics stockholders approve share increases and board elections - Investing.com
CytomX Therapeutics stockholders approve share increases and board elections By Investing.com - Investing.com Canada
Form 8K CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
CytomX (CTMX) director Su Zhen awarded 59,000 stock options at $2.96 - Stock Titan
[8-K] CytomX Therapeutics, Inc. Reports Material Event - Stock Titan
Director at CytomX (NASDAQ: CTMX) awarded 59,000 stock options - Stock Titan
Director at CytomX (NASDAQ: CTMX) receives 59,000-stock option award - Stock Titan
CytomX (CTMX) director receives 59,000 stock options at $2.96 - Stock Titan
CytomX (CTMX) director Halley Gilbert receives 59,000 stock options at $2.96 strike - Stock Titan
CytomX (CTMX) director Alan Ashworth receives grant of 59,000 stock options - Stock Titan
CytomX (CTMX) director Elaine Jones awarded 59,000 stock options at $2.96 strike - Stock Titan
Is CytomX (CTMX) Poised for Growth Following Expanded Regeneron Partnership?Revenue Estimate Trend - DonanımHaber
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now? - Insider Monkey
CytomX Therapeutics Inc (CTMX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CytomX CFO Ogden sells $4,953 in company stock By Investing.com - Investing.com South Africa
CytomX CFO Ogden sells $4,953 in company stock - Investing.com
CytomX Therapeutics (CTMX) CFO sells shares to cover RSU tax withholding - Stock Titan
10 Best Growth Stocks Under $30 to Buy Now - Insider Monkey
CytomX Therapeutics Inc (CTMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytomx Therapeutics Inc Stock (CTMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chu Yu-Waye | Chief Medical Officer |
Mar 17 '26 |
Sale |
6.42 |
21,279 |
136,675 |
189,446 |
| McCarthy Sean A. | CEO |
Mar 17 '26 |
Sale |
6.42 |
118,969 |
764,138 |
1,078,922 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Mar 17 '26 |
Sale |
6.42 |
31,492 |
202,273 |
300,760 |
| Ogden Christopher | Chief Financial Officer |
Mar 17 '26 |
Sale |
6.42 |
19,323 |
124,112 |
296,948 |
| McCarthy Sean A. | CEO |
Nov 06 '25 |
Sale |
4.54 |
101,793 |
461,906 |
987,891 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):